Optimization of atrial natriuretic factor radioimmunoassay.
The development and long-term performance of a radioimmunoassay method for cardionatrin (C I = ANF 99-126) is described. The method was evaluated for accuracy, specificity and precision using different protocols and in various species. The antiserum raised against C I cross-reacts 100% with both human and rat C I and 122% with cardionatrin IV (C IV = ANF 1-126). Dextran-coated charcoal (DCC) and double antibody (DA) disequilibrium protocols were used for the separation of free from antibody-bound radioactivity. The sensitivity, coefficient of variation within assay and between assay for DCC was 4.6 pg/tube, 3.1% and 13.8% respectively, and 1.5 pg/tube, 3.8% and 9.1% for the DA. The mean normal plasma C I levels in human, rat and dog after plasma acidification and extraction using the DA method was 49.7 +/- 4.0; 253.6 +/- 19.6 and 59.9 +/- 3.4 pg/mL respectively.
Sarda
I R
IR
University of Ottawa Heart Institute, Ottawa Civic Hospital, Ontario, Canada.
de Bold
M L
ML
de Bold
A J
AJ
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000097:blood*; D004285:Dogs; D006801:Humans; D007106:Immune Sera; D017830:Octoxynol; D011092:Polyethylene Glycols / Q000494:pharmacology; D011863:Radioimmunoassay / Q000379:methods*; D051381:Rats
D007106:Immune Sera; D011092:Polyethylene Glycols; D009320:Atrial Natriuretic Factor; D017830:Octoxynol; D007611:Aprotinin